At a glance
- Originator Aventis
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 23 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
- 10 Jul 1997 Preclinical development for Inflammation in France (Unknown route)
- 11 Jun 1997 Preclinical development for Pain in France (Unknown route)